Overview
Ovarian cancer is the most lethal gynecological malignancy, with approximately 314,000 new cases and 207,000 deaths annually worldwide. Its poor prognosis stems largely from late-stage diagnosis (>70% at stage III/IV) and the development of chemoresistance. From a metallomics perspective, ovarian cancer sits at the intersection of metalloestrogen biology, iron-driven cell death (ferroptosis), and an emerging understanding of the peritoneal and tumor-associated microbiome. The metallomic dimension offers both mechanistic insight and potential therapeutic targets, particularly through ferroptosis-inducing strategies.
Metalloestrogen Connections
Cadmium as Metalloestrogen
Cadmium is the most established metalloestrogen relevant to ovarian cancer:
- Cd binds estrogen receptor alpha (ERa) with a dissociation constant (Kd) of approximately 4.5 x 10^-10 M — nearly equivalent to estradiol
- Cd activates ER-dependent gene transcription in ovarian cancer cell lines at concentrations as low as 1 uM
- Cd also signals through the membrane-bound estrogen receptor GPR30/GPER, inducing proliferative responses in ER-negative cells at 50-500 nM
- Epidemiological studies have linked urinary and blood Cd levels with increased ovarian cancer risk, though results are inconsistent across populations
- Cd's half-life in the body is 12-30 years, meaning chronic low-level exposure produces cumulative ovarian tissue burden
- Smoking is the primary non-occupational Cd exposure source; dietary Cd from contaminated soils (phosphate fertilizers) adds chronic background exposure
- See cadmium and metalloestrogens for broader mechanisms
Nickel and Arsenic
- nickel binds ERa noncompetitively with estradiol and induces cell growth in hormone-sensitive cell lines
- Ni also drives epigenetic changes — global loss of histone acetylation, H3K9 methylation — that may promote ovarian carcinogenesis independently of estrogenic effects
- arsenic exposure is associated with increased ovarian cancer risk through oxidative stress, DNA damage, and interference with DNA repair pathways
- Co-exposure to multiple metals (Cd + Ni + As) may produce synergistic carcinogenic effects through converging estrogenic and epigenetic mechanisms
Iron and Ferroptosis
Iron Dysregulation in Ovarian Cancer
- Ovarian cancer cells exhibit altered iron metabolism with upregulation of transferrin receptor 1 (TfR1) and downregulation of ferroportin, creating an iron-accumulating phenotype
- Elevated intracellular iron drives Fenton chemistry, generating reactive oxygen species (ROS) that promote genomic instability
- Endometriosis-associated ovarian cancers (clear cell and endometrioid subtypes) develop in an iron-rich environment from repeated retrograde menstruation and hemoglobin breakdown
Ferroptosis as Therapeutic Target
Ferroptosis — iron-dependent regulated cell death driven by lipid peroxidation — has emerged as a promising therapeutic strategy:
- Ovarian cancer cells with high iron content are particularly vulnerable to ferroptosis induction
- Erastin and RSL3 (GPX4 inhibitors) trigger ferroptosis in cisplatin-resistant ovarian cancer cells
- Combination of ferroptosis inducers with conventional chemotherapy may overcome platinum resistance
- The cystine/glutamate antiporter (system Xc-) is a key target; its inhibition depletes glutathione and sensitizes cells to ferroptosis
- Iron chelation paradoxically reduces ferroptosis susceptibility, confirming iron's central role
- See ferroptosis for detailed pathway mechanisms
Tumor and Peritoneal Microbiome
Distinct Tumor-Associated Microbiome
- Ovarian cancer tissues harbor a distinct microbiome compared to normal ovarian tissue and adjacent peritoneum
- Fusobacterium enrichment has been documented in ovarian cancer tissue, paralleling its well-established role in colorectal cancer
- Fusobacterium nucleatum promotes tumor progression through FadA adhesin binding to E-cadherin, activating beta-catenin signaling and NF-kB-mediated inflammation
- See fusobacterium for detailed mechanisms
Peritoneal Microbiome
- The peritoneal cavity, long assumed sterile, harbors a low-biomass microbiome that is altered in ovarian cancer
- Ascitic fluid from ovarian cancer patients contains distinct bacterial communities compared to benign conditions
- Peritoneal microbiome composition may influence the tumor immune microenvironment and response to immunotherapy
Mycobiome
- Fungal communities (mycobiome) in ovarian cancer are an emerging area of investigation
- Candida and Malassezia species have been identified in ovarian tumor tissue
- Fungal beta-glucans can activate complement and modulate anti-tumor immunity through Dectin-1 receptor signaling
- The mycobiome may interact with bacterial communities to shape the overall tumor microenvironment
Environmental and Dietary Metal Exposure
| Source | Metals | Relevance |
|---|---|---|
| Smoking | Cd (primary) | 35-50% higher Cd body burden in smokers |
| Diet | Cd, As, Ni | Contaminated soils, rice, shellfish, leafy greens |
| Occupational | Cd, Ni, As | Battery production, smelting, electronics |
| Talc | As, trace metals | Historical concern for perineal talc use |
| Water | As | Arsenic-contaminated groundwater in endemic areas |
Open Questions
- Can ferroptosis-inducing agents overcome platinum resistance in recurrent ovarian cancer?
- Does the ovarian tumor microbiome composition predict chemotherapy response?
- What is the relative contribution of Cd metalloestrogen signaling vs. genetic/hormonal risk factors?
- Can peritoneal microbiome profiling improve early detection through liquid biopsy of ascitic fluid?
- Do mycobiome-bacteria interactions in the peritoneal cavity influence ovarian cancer progression?
Connections
- metalloestrogens — Cd and Ni as ERa-binding metals driving ovarian cell proliferation
- cadmium — Primary metalloestrogen; mammary and ovarian accumulation; smoking as exposure source
- nickel — Epigenetic carcinogenesis via histone modification; noncompetitive ERa binding
- iron — Iron accumulation in endometriosis-associated subtypes; Fenton chemistry
- ferroptosis — Iron-dependent cell death as therapeutic target; GPX4 inhibition in cisplatin-resistant cells
- fusobacterium — Enriched in ovarian tumor tissue; FadA-mediated E-cadherin/beta-catenin activation